• Y-27632 Dihydrochloride: Advancing iPSC and Neuropsychiatric

  2026-07-07

  Explore how Y-27632 dihydrochloride, a potent ROCK inhibitor, is transforming stem cell and neuropsychiatric research. This article uniquely bridges selective ROCK inhibition to advanced iPSC applications, highlighting practical assay insights and new frontiers.

• Bazedoxifene Targets IL-6/GP130 Signaling in Cancer Therapy

  2026-07-06

  The referenced study highlights Bazedoxifene’s novel role as an inhibitor of the IL-6/GP130 signaling pathway, expanding its utility beyond osteoporosis to potential oncological applications. This review synthesizes mechanistic findings, therapeutic implications, and protocol considerations for researchers investigating selective estrogen receptor modulators in cancer biology.

• Gramine: Precision Ferroptosis Inducer for Cancer Biology Re

  2026-07-06

  Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) is emerging as a game-changing ferroptosis inducer for triple-negative breast cancer studies. Explore how APExBIO’s high-purity Gramine accelerates mechanistic workflows, enables reproducible ferroptosis assays, and offers actionable troubleshooting insights for cancer biology research.

• RNA Pol II Inhibition Triggers Apoptosis via Active Signalin

  2026-07-05

  Harper et al. (2025) reveal that cell death upon RNA Pol II inhibition is not a passive consequence of transcriptional shutdown, but rather results from an active apoptotic pathway triggered by the loss of hypophosphorylated RNA Pol IIA. This mechanistic insight reframes how researchers interpret drug-induced cytotoxicity and supports new strategies for interrogating cell death in cancer models.

• ML133 HCl: Advancing Kir2.1 Inhibition in Vascular Remodelin

  2026-07-04

  Explore how ML133 HCl, a highly selective potassium channel inhibitor, is redefining experimental strategy in translational research on pulmonary artery smooth muscle cell proliferation. Integrating breakthrough mechanistic data and workflow guidance, this article offers nuanced insight for cardiovascular investigators seeking to leverage Kir2.1 channel biology for disease modeling and therapeutic innovation.

• AS1842856 Foxo1 Inhibitor: Advancing MSC & Metabolic Researc

  2026-07-03

  AS1842856 empowers researchers to precisely inhibit Foxo1 activity, unlocking detailed mechanistic insight into gluconeogenesis and stem cell activation. With robust performance in both in vitro and in vivo models, this APExBIO tool is redefining experimental workflows in metabolic and bone biology.

• CircRNA hsa_circ_0001944 Modulates FXR/TLR4 and Ferroptosis

  2026-07-03

  This study elucidates how hsa_circ_0001944 regulates the FXR/TLR4 pathway and ferroptosis, mitigating nickel oxide nanoparticle-induced collagen deposition in hepatic stellate cells. By integrating FXR agonist GW4064 and bioinformatics, the research clarifies the crosstalk between non-coding RNA, nuclear receptor signaling, and ferroptosis in liver fibrosis models, offering new mechanistic insights for metabolic and fibrosis research.

• PD 0332991 (Palbociclib) HCl: Applied CDK4/6 Inhibition in C

  2026-07-02

  PD 0332991 (Palbociclib) HCl empowers researchers with reproducible, nanomolar-precision CDK4/6 inhibition for advanced studies in breast cancer and multiple myeloma. This guide details experimental workflows, optimization, and troubleshooting for robust G1 cell cycle arrest and reliable antiproliferative readouts.

• Aclacinomycin A: Mechanistic Leverage for DNA Damage Researc

  2026-07-02

  This article offers translational researchers a mechanistic and strategic guide to leveraging Aclacinomycin A (Aclarubicin) as a high-fidelity model of DNA damage and apoptosis. Grounded in recent advances on ribosomal DNA lesions and PML-nucleolar dynamics, it delineates actionable protocols, competitive context, and visionary implications for genome stability and cancer biology. The discussion integrates evidence from foundational studies and expands beyond conventional product pages to stimulate new experimental approaches.

• MAPK10 Controls NSCLC Metastasis via KRT16 Ubiquitination Ax

  2026-07-01

  This study reveals that MAPK10 suppresses non-small cell lung cancer (NSCLC) metastasis by promoting phosphorylation-dependent ubiquitination and degradation of keratin 16 (KRT16). The MAPK10/KRT16/RNF213 signaling pathway emerges as a prognostic marker and potential therapeutic target, with implications for personalized lung cancer treatment strategies.

• Cabazitaxel (XRP6258): Technical Use in Resistant Tumor Mode

  2026-07-01

  Cabazitaxel (XRP6258) is designed for disrupting microtubule dynamics in taxane-resistant cancer models, particularly those expressing P-glycoprotein. It is unsuitable for water-based assays and long-term solution storage, but offers reliable performance in DMSO- or ethanol-based workflows.

• G-Quadruplex Modulation of TDP-43 Aggregation and Toxicity

  2026-06-30

  Oldani et al. (2025) demonstrate that RNA G-quadruplexes directly influence TDP-43 protein condensation and toxicity in vitro and across multiple cell models. Their findings reveal a previously underappreciated structural mechanism in neurodegenerative proteinopathies, highlighting the potential of G-quadruplex–targeting strategies in therapeutic development.

• KU-60019: ATM Kinase Inhibitor Transforming DNA Damage Resea

  2026-06-30

  Explore how KU-60019, a potent ATM kinase inhibitor, advances DNA damage response research through precision assay design and novel mechanistic insights. Discover protocol strategies, unique reference findings, and actionable guidance for glioma radiosensitization.

• Tropisetron Hydrochloride: 5-HT3 Receptor Antagonist in Adva

  2026-06-29

  Tropisetron Hydrochloride enables precise modulation of serotonin and nicotinic receptor signaling, making it indispensable for neuroscience and renal transporter research. Explore optimized workflows, troubleshooting strategies, and the latest transporter inhibition insights, all supported by high-purity APExBIO supply.

• Lactobacillus gasseri ATCC33323 Modulates Colitis via NR1I3–

  2026-06-29

  This study elucidates a mechanistic link between Lactobacillus gasseri ATCC33323 administration and improved intestinal barrier integrity in DSS-induced colitis, highlighting the regulatory role of NR1I3 in E-cadherin expression. The findings advance our understanding of probiotic-based interventions for inflammatory bowel disease and provide a framework for mechanistic studies in barrier function genetics.

449 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page